LPPR

Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France

Retrieved on: 
Wednesday, March 1, 2023
Oncology, Medical Devices, Health, Other Health, General Health, Biotechnology, Skin, Social, III, Official Journal, Temozolomide, TMZ, LPPR, Patient, Progression-free survival, Commission nationale de l'informatique et des libertés, Neoplasm, ASA, Official Journal of the European Union, HR, GBM, Glioblastoma, CE, Physician, Light, Medical imaging, Nursing, Alternating electric field therapy

Novocure (NASDAQ:NVCR) today announced the reimbursement and availability of Optune together with temozolomide (TMZ) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) in France.

Key Points: 
  • Novocure (NASDAQ:NVCR) today announced the reimbursement and availability of Optune together with temozolomide (TMZ) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) in France.
  • "We are pleased to make Optune available to French patients and healthcare professionals for the treatment of glioblastoma,” said Anne Calixte de Lembeye, General Manager of Novocure France.
  • We are energized and prepared to support patients in France as they begin to use our therapy as an additional treatment choice for newly diagnosed GBM."
  • “We are proud that Optune is now a treatment choice for newly diagnosed GBM patients in France.

InspireMD Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 9, 2021
Stent, Evaluation, Call, HAS, LPPR, JACC, Industry, Medical device, Clinical trial, EPS, CAD, CEO, Safety, COVID, Growth, Stroke, COVID-19, NSPR, Principal, Stenosis, Partnership, Efficacy, Multicenter trial, Palestinian National Authority, Hospital, Company, GLOBE, Randomized controlled trial, National Commission, Physician, American College of Cardiology, Marketing, Nasdaq, Patient, TEL, FDA, American College, Animal, Pharmaceutical industry, Health insurance

TEL AVIV, Israel, Nov. 09, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced financial and operating results as of and for the third quarter ended September 30, 2021.

Key Points: 
  • For the nine months ended September 30, 2021, CGuard revenue increased by 45.4% compared to the same period in 2020.
  • Financial Results for the Third Quarter ended September 30, 2021
    For the three months ended September 30, 2021, revenue increased by $91,000, or 9.3%, to $1,071,000, from $980,000 during the three months ended September 30, 2020.
  • Total operating expenses for the quarter ended September 30, 2021 were $4,123,000, an increase of 65.4% compared to $2,493,000 for the same period in 2020.
  • For the three months ended September 30, 2021, financial expenses increased by 5.3%, or $2,000, to $40,000, from $38,000 during the three months ended September 30, 2020.

InspireMD Receives Reimbursement Approval for CGuard™ Embolic Prevention System from the French National Authority for Health

Retrieved on: 
Wednesday, October 13, 2021
Risk, Technology, Industry, HAS, Nasdaq, Senior, Stenosis, EPS, National Commission, Physician, Marketing, Security (finance), Compliance, Trademark dilution, SEC, LPPR, Medical device, Clinical trial, CAD, GLOBE, U.S. Securities and Exchange Commission, Company, Forward-looking statement, CEO, TEL, Evaluation, Sale, Stroke, NSPR, Safety, Palestinian National Authority, Xi, Pharmaceutical industry

The CGuard EPS Self-Expanding Carotid Stent is the latest generation open-cell nitinol self-expanding stent with patented MicroNet mesh technology designed to prevent the risk of early and late embolism.

Key Points: 
  • The CGuard EPS Self-Expanding Carotid Stent is the latest generation open-cell nitinol self-expanding stent with patented MicroNet mesh technology designed to prevent the risk of early and late embolism.
  • This milestone now provides physicians in France with the choice to use CGuard EPS in the treatment of carotid artery disease and stroke prevention.
  • We believe that the unique and proprietary design of our system, is the most advanced and safest stent system on the market today, said Marvin Slosman, CEO of InspireMD.
  • The CGuard carotid stent, is commercially established in 33 markets to date, adding France to our growing global expansion.